Literature DB >> 8039602

Aldose reductase catalysis and crystallography. Insights from recent advances in enzyme structure and function.

J M Petrash1, I Tarle, D K Wilson, F A Quiocho.   

Abstract

Enhanced metabolism of glucose via the polyol pathway may play an important role in the pathogenesis of diabetic retinopathy, neuropathy, and nephropathy. Aldose reductase catalyzes the NADPH-dependent conversion of glucose to sorbitol, the first step in the polyol pathway. Interruption of the polyol pathway by inhibition of aldose reductase holds considerable promise as a therapeutic measure to prevent or delay the onset and severity of these late complications of diabetes. Dramatic advances in our understanding of the molecular biology, enzymology, and three-dimensional structure of aldose reductase have occurred in recent years, providing new and challenging insights into the enzyme's catalytic mechanism. Recent developments in structure determination of aldose reductase and the implications for evaluation and development of aldose reductase inhibitors are summarized.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039602     DOI: 10.2337/diab.43.8.955

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  12 in total

Review 1.  Comparative anatomy of the aldo-keto reductase superfamily.

Authors:  J M Jez; M J Bennett; B P Schlegel; M Lewis; T M Penning
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

2.  NAD(P)H-dependent aldose reductase from the xylose-assimilating yeast Candida tenuis. Isolation, characterization and biochemical properties of the enzyme.

Authors:  W Neuhauser; D Haltrich; K D Kulbe; B Nidetzky
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

3.  Kinetic alteration of a human dihydrodiol/3alpha-hydroxysteroid dehydrogenase isoenzyme, AKR1C4, by replacement of histidine-216 with tyrosine or phenylalanine.

Authors:  T Ohta; S Ishikura; S Shintani; N Usami; A Hara
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

4.  Differential control of murine aldose reductase and fibroblast growth factor (FGF)-regulated-1 gene expression in NIH 3T3 cells by FGF-1 treatment and hyperosmotic stress.

Authors:  D K Hsu; Y Guo; K A Peifley; J A Winkles
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

5.  Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases/reductases and aldo-keto reductases with retinoids.

Authors:  Oriol Gallego; Olga V Belyaeva; Sergio Porté; F Xavier Ruiz; Anton V Stetsenko; Elena V Shabrova; Natalia V Kostereva; Jaume Farrés; Xavier Parés; Natalia Y Kedishvili
Journal:  Biochem J       Date:  2006-10-01       Impact factor: 3.857

Review 6.  Aldose reductase, oxidative stress and diabetic cardiovascular complications.

Authors:  Srinivasan Vedantham; Radha Ananthakrishnan; Ann Marie Schmidt; Ravichandran Ramasamy
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2012-09

Review 7.  Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model.

Authors:  Ravichandran Ramasamy; Ira J Goldberg
Journal:  Circ Res       Date:  2010-05-14       Impact factor: 17.367

8.  Purification from rat liver of a novel constitutively expressed member of the aldo-keto reductase 7 family that is widely distributed in extrahepatic tissues.

Authors:  V P Kelly; L S Ireland; E M Ellis; J D Hayes
Journal:  Biochem J       Date:  2000-06-01       Impact factor: 3.857

9.  Activation of human liver 3 alpha-hydroxysteroid dehydrogenase by sulphobromophthalein.

Authors:  K Matsuura; Y Tamada; Y Deyashiki; Y Miyabe; M Nakanishi; I Ohya; A Hara
Journal:  Biochem J       Date:  1996-01-01       Impact factor: 3.857

10.  Design of an amide N-glycoside derivative of β-glucogallin: a stable, potent, and specific inhibitor of aldose reductase.

Authors:  Linfeng Li; Kun-Che Chang; Yaming Zhou; Biehuoy Shieh; Jessica Ponder; Adedoyin D Abraham; Hadi Ali; Anson Snow; J Mark Petrash; Daniel V LaBarbera
Journal:  J Med Chem       Date:  2013-12-23       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.